Kiniksa Pharmaceuticals International, plc Increase (Decrease) in Contract with Customer, Asset
Kiniksa Pharmaceuticals International, plc (KNSA) reported Increase (Decrease) in Contract with Customer, Asset of -$7.66 million for the 12-month period ending 2023-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerAsset · last filed 2026-02-24
- Kiniksa Pharmaceuticals International, plc increase (decrease) in contract with customer, asset for the quarter ending 2023-12-31 was $0.00.
- Kiniksa Pharmaceuticals International, plc increase (decrease) in contract with customer, asset for the quarter ending 2023-09-30 was $0.00.
- Kiniksa Pharmaceuticals International, plc increase (decrease) in contract with customer, asset for the quarter ending 2023-06-30 was $0.00.
- Kiniksa Pharmaceuticals International, plc increase (decrease) in contract with customer, asset for the quarter ending 2023-03-31 was -$7.66M.
- Kiniksa Pharmaceuticals International, plc increase (decrease) in contract with customer, asset for fiscal 2023 was -$7.66M, a 200.00% decline from fiscal 2022.
- Kiniksa Pharmaceuticals International, plc increase (decrease) in contract with customer, asset for fiscal 2022 was $7.66M.
| Period end | Increase (Decrease) in Contract with Customer, Asset 3 month | Increase (Decrease) in Contract with Customer, Asset 6 month | Increase (Decrease) in Contract with Customer, Asset 9 month | Increase (Decrease) in Contract with Customer, Asset 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | $0.00 derived: sum of 2 quarters · filed 2026-02-24 | $0.00 derived: sum of 3 quarters · filed 2026-02-24 | -$7.66M 10-K · filed 2026-02-24 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-29 | $0.00 derived: sum of 2 quarters · filed 2024-10-29 | -$7.66M 10-Q · filed 2024-10-29 | |
| 2023-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-25 | -$7.66M 10-Q · filed 2024-07-25 | ||
| 2023-03-31 | -$7.66M 10-Q · filed 2024-04-25 | |||
| 2022-12-31 | $7.66M 10-K · filed 2025-02-25 |